J Am Soc Nephrol. 2026 Nov 15. doi: 10.1681/ASN.0000001333. Online ahead of print.
ABSTRACT
BACKGROUND: Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS).
METHODS: The FIND-CKD trial randomized 1584 adults with nondiabetic CKD (eGFR ≥25 to <60 ml/min/1.73 m2 and urinary albumin-to-creatinine ratio [UACR] ≥200 to <500 mg/g, or eGFR ≥25 to <90 ml/min/1.73 m2 and UACR ≥500 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg) or placebo. Reported outcomes include total eGFR slope (baseline to month 32; FIND-CKD primary outcome), a kidney composite (sustained ≥57% eGFR decline from baseline or kidney failure; FIND-CKD secondary outcome), changes in urinary protein-to-creatinine ratio (UPCR; exploratory outcome), and adverse events (safety outcome).
RESULTS: Among the 215 participants with FSGS, mean (SD) baseline eGFR was 45 (17) ml/min/1.73 m2, and median (Q1, Q3) UPCR was 1427 (947, 2120) mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS. Finerenone reduced the total eGFR slope versus placeboby 1.3 ml/min/1.73 m2/year (95% CI, 0.5-2.2; P=0.002). This effect was consistent among the 167 (78%) participants with a biopsy-proven FSGS diagnosis (1.4 ml/min/1.73 m2/year), and among participants with primary or secondary FSGS (P-interaction 0.84). Finerenone yielded a hazard ratio of 0.58 (95% CI, 0.30-1.15) versus placebo for the kidney composite outcome. From baseline to month 12, finerenone lowered UPCR by 41% (95% CI, 26%-53%) versus placebo and increased the likelihood of achieving UPCR <700 mg/g (odds ratio at month 12: 6.8 [95% CI, 3.0-17.2]). A post hoc exploratory proteomics analysis showed that finerenone versus placebo reduced markers of fibrosis, inflammation, and components of the filtration barrier. Hyperkalemia-related adverse events occurred in 15 (15%) and 23 (20%) participants assigned to finerenone or placebo, respectively.
CONCLUSIONS: Finerenone was well-tolerated and preserved kidney function, lowered proteinuria, and reduced markers of fibrosis, inflammation, and components of filtration barrier in FIND-CKD participants with FSGS.
PMID:43034991 | DOI:10.1681/ASN.0000001333

